Unternehmen UNT-2103-MAT
Headline
SurgMark is launching a novel, urgently needed tissue marker for breast cancer diagnosis. SchurSign is bio-absorbable, pain free, and true-to-site and will be introduced in the US in two years.
Beschreibung des Unternehmens
Unternehmensgegenstand (Geschäftskonzept, -idee)
SurgMark is a medical device company developing an innovative marker for breast biopsies, the current standard diagnostic process to mark suspicious tissue, and confirmed tumors prior to neoadjuvant therapy.
Our biomaterial based and fully resorbable SchurSignTM marker will enter a rapidly growing market for breast biopsy tools (CAGR 10%), with current market volume of ~100 Mill. $ expected.
The biomaterial has already been successfully introduced as implant in surgery and in wound healing by the SurgMark founders. We therefore expect to receive FDA approval as early as end of 2021 and start commercialization of SchurSignTM early 2022, by selling it in the US through our partners.
Key opinion leaders, lead investors and strategic partners have already confirmed their interest and negotiations are ongoing.
SurgMark is presently raising 1 to 1.5 million EUR required to carry SchurSign through approval and early commercialization phases.
Mehr über dieses Unternehmen
Möchten Sie mehr über dieses Unternehmen erfahren (u.a. Markt und Wettbewerb, Management und Mitarbeiter sowie Kapitalbedarf), dann müssen Sie sich hierzu einloggen oder anmelden.
